Evidence mapPaperPMID 31183921Full record

Trial reportPhytotherapy research : PTR2019

Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized, controlled study.

Carolina B Ribeiro, Fernanda M Ramos, John A Manthey, Thais B Cesar

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Phytotherapy research : PTR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06005142 (Therapeutic Intervention of Nutraceutical Eriomin Associated with Metformin to Improve the Control of Hyperglycemia in Patients with Prediabetes), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06005142 naactive not recruitingnot on this mapstarted 2024, after this paper: background citation

Therapeutic Intervention of Nutraceutical Eriomin Associated with Metformin to Improve the Control of Hyperglycemia in Patients with Prediabetes: a Double-blind, Randomized, Placebo-controlled Crossover Clinical Trial

TypeinterventionalSponsorThais CesarRan2024 to 2024Enrolled80ConditionsPre-diabetesArmsEriomin, Washout, Placebo
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. The Lemon Flavonoid EriominInternational journal of molecular sciences · 2025
    Article
  8. Citrus Flavonoids as Antimicrobials.Chemistry & biodiversity · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carolina B RibeiroDepartment of Food and Nutrition, School of Pharmaceutical Sciences, Sao Paulo State University-UNESP, Araraquara, São Paulo, Brazil.
Fernanda M RamosDepartment of Food and Nutrition, School of Pharmaceutical Sciences, Sao Paulo State University-UNESP, Araraquara, São Paulo, Brazil.
John A MantheyU.S. Horticultural Research Laboratory, Agricultural Research Service, USDA, Port Fierce, Florida.ORCID https://orcid.org/0000-0001-9122-0460
Thais B CesarDepartment of Food and Nutrition, School of Pharmaceutical Sciences, Sao Paulo State University-UNESP, Araraquara, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-7878-7075

Funding

Ingredients by Nature™ 5045
6 · The paper itself

Abstract

This study evaluated the potential effectiveness of different doses of Eriomin® on hyperglycemia and insulin resistance associated with other metabolic biomarkers in prediabetic individuals. Prediabetes patients (n = 103, 49 ± 10 years) were randomly divided into four parallel groups: (a) Placebo; (b) Eriomin 200 mg; (c) Eriomin 400 mg; and (d) Eriomin 800 mg. Assessment of biochemical, metabolic, inflammatory, hepatic, renal, anthropometric markers, blood pressure, and dietary parameters were performed during 12 weeks of intervention. Treatment with all doses of Eriomin (200, 400, and 800 mg) had similar effects and altered significantly the following variables: blood glucose (-5%), insulin resistance (-7%), glucose intolerance (-7%), glycated hemoglobin (-2%), glucagon (-6.5%), C-peptide (-5%), hsCRP (-12%), interleukin-6 (-13%), TNFα (-11%), lipid peroxidation (-17%), systolic blood pressure (-8%), GLP-1 (+15%), adiponectin (+19%), and antioxidant capacity (+6%). Eriomin or placebo did not influence the anthropometric and dietary variables. Short-term intervention with Eriomin, at doses of 200, 400, or 800 mg/day, benefited glycemic control, reduced systemic inflammation and oxidative stress, and reversed the prediabetic condition in 24% of the evaluated patients.

Indexed as

AdultBlood GlucoseCitrusDouble-Blind MethodFemaleFlavanonesGlycated HemoglobinHesperidinHumansHyperglycemiaHypoglycemic AgentsInsulin ResistanceMaleMiddle AgedPrediabetic StateTreatment OutcomeBlood GlucoseeriocitrinFlavanonesGlycated HemoglobinHesperidinHypoglycemic Agentsnaringinflavonoidshyperglycemiainsulin resistanceprediabetic state

Identifiers

PMID31183921
PMCPMC6618084

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.